– Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline ...

– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

Please provide your email address to receive an email when new articles are posted on . EMPHASIS study included 258 persons with MS given vidofludimus calcium or placebo for 24 weeks. Results show ...

Please provide your email address to receive an email when new articles are posted on . A post hoc analysis indicates VidoCa administration could help prevent long-term fatigue. The drug’s antiviral, ...

– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes – – NfL Effect in ...

Investigational vidofludimus calcium missed its primary target in an exploratory phase II study of progressive multiple sclerosis (MS) but showed promising disability-related trends, data from the ...

– Vidofludimus Calcium's Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activations in Preclinical Models – – Top-Line Data from Phase 2 CALLIPER ...

NEW YORK, June 15, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating ...

Issuer: Immunic AG / Key word (s): Study results Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 ...